Aizon is on a mission to integrate modern computing into the complex arena of GMP manufacturing processes in life sciences.

In the latest episode of the PharmaSource podcast we sat down with Claus Abildgren, Chief Revenue Officer at Aizon, and David O’Gara, Strategic Advisor to Aizon to understand how artificial intelligence can make an impact on manufacturing in the highly-regulated industry.

“Our goal is to evolve the industry by taking pragmatic steps towards enhancing manufacturing performance through practical applications.” says Claus. “We aim to optimize the current capacity of manufacturers and utilize artificial intelligence to anticipate and mitigate the risk of adverse events with predictive capabilities.”

When producing drug products under stringent GMP conditions, “ensuring quality is fundamental. This includes securing data integrity and maintaining comprehensive audit trails—key aspects of deploying technology in a highly regulated environment.”

Leveraging the data generated at a plant leads to identifying opportunities for yield improvements, thereby ensuring high-quality production, delivered on time and at reasonable costs. says David.

“Automated quality reports can significantly reduce the workload for quality organizations and production plant chemists.”

Deploying this technology, especially at CDMOs and for their sponsors, can yield substantial returns, particularly with high-value molecules where even a 1% improvement can have a remarkable impact on return on investment.

Read the full article